PUBLISHER: IMARC | PRODUCT CODE: 1390555
PUBLISHER: IMARC | PRODUCT CODE: 1390555
The global spine biologics market size reached US$ 2.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2028, exhibiting a growth rate (CAGR) of 3.79% during 2022-2028.
Spine biologics are materials that alter the surrounding environment through active cellular processes. They promote growth and differentiation and aid in the repair and healing of an injury. They also reduce the frequency of primary or additional surgical procedures and decrease the disruption of soft tissue. At present, a wide variety of spine biologics are used as an alternative to conventional treatments. For instance, pedicle screws and rods find application in a spine fusion procedure to provide spinal stabilization, thereby promoting healing. Moreover, continuous advancements are promoting the repair and regeneration of cartilaginous and bony structures.
Spine fusion is utilized as a tool in the treatment of spine trauma, tumors, and degenerative disorders. However, its poor outcomes can lead to serious complications among patients. This, in confluence with a significant increase in the number of individuals with acute and chronic conditions represents one of the key factors positively influencing the use of spine biologics around the world. Spine biologics impact fusion at the cellular level, which helps achieve successful arthrodesis in the treatment of symptomatic deformity or instability. Moreover, there is a rise in the geriatric population globally, which is more susceptible to musculoskeletal conditions. This, along with the growing prevalence of orthopedic conditions, is catalyzing the demand for spine biologics worldwide. Apart from this, the escalating demand for non-surgical procedures is encouraging the use of spinal biologics in minimally invasive lumbar surgeries. Spine biologics are also gaining traction as a replacement for metal hardware and in individual natural bone grafts or allografts. Furthermore, the growing access to healthcare services on account of inflating income levels is contributing to market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global spine biologics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, surgery type and end user.
Spinal Allografts
Machined Bones Allograft
Demineralized Bone Matrix
Bone Graft Substitutes
Bone Morphogenetic Proteins
Synthetic Bone Grafts
Cell Based Matrix
Open Spine Surgery
Minimally Invasive Spine Surgery
Hospitals
Ambulatory Care Centers
Spinal Surgery Centers
Orthopedic Clinics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Arthrex Inc, Alphatec Holdings Inc., Exactech Inc, Johnson & Johnson, Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V. and Zimmer Biomet.